Advanced Filters
noise

Winchester, Massachusetts Clinical Trials

A listing of Winchester, Massachusetts clinical trials actively recruiting patient volunteers.

Found 2,374 clinical trials
K Kofi Effa Ababio

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

16 years of age All Phase 1
A Adam Jaroszewski, Ph.D.

A One-Arm Open Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior

This study aims to evaluate the acceptability, safety, and preliminary efficacy of a smartphone-delivered intervention called Therapeutic Evaluative Conditioning for Suicide (TEC-S) in reducing suicidal thoughts and behaviors (STB) among adults with recent and frequent suicide ideation.

18 years of age All Phase N/A
S Samuel Snider

REstoring CONsciousness With NEurostimulation of the Central Thalamus: The RECONNECT Study

The RE-CONNECT study is an early feasibility study to establish the safety, feasibility, and efficacy of two central thalamic deep brain stimulation targets in patients with chronic disorders of consciousness.

18 - 55 years of age All Phase 0
G Glenn Hanna, MD

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

This research study is studying the effect of different drugs as possible treatments for salivary and other head and neck cancers/ The name of the study intervention involved in this study is: \-- implantable microdevice

18 years of age All Phase 0
D Dost Ongur, MD PhD

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

The goal of this double-blind, placebo-controlled randomized clinical trial is to test the effect of 12 weeks of orally administered MitoQ (mitoquinol mesylate) supplementation on cognition in 50 people with early phase schizophrenia-spectrum disorders (E-SSD) who have mitochondrial dysfunction (called high risk, or HR). Cognitive impairments in SSD can cause …

18 - 35 years of age All Phase 2/3
S Samuel Kukler

Mind Body Intervention for Chronic Upper Extremity Pain (Repetitive Stress Injury)

The goal of this nonrandomized pilot study is to test a mind-body interventional approach for the treatment of chronic upper extremity pain or repetitive stress injury of the upper extremity (wrist/shoulder/elbow). To determine if a mind-body intervention improves upper extremity functional capacity (ie., Disability of Arm Shoulder Hand - DASH) …

18 - 60 years of age All Phase N/A

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced …

18 years of age All Phase 1
I Isabel Kristan

Psilocybin in Cancer Pain Study

The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer. The name of the study intervention used in this research study is: Psilocybin (a tryptamine derivative)

18 years of age All Phase 2
R Richard A Newcomb, MD

Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation

Primary PC - or training HCT clinicians to deliver PC domains as part of routine practice - is an alternative model of supportive care. We have developed Sentinel, a primary PC intervention for HCT clinicians and patients. This study will assess Sentinel's feasibility and acceptability.

18 years of age All Phase N/A
S Sebastian Unizony, MD

CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

The purpose of this study is to evaluate the safety of CC-97540 in relapsed or refractory severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

18 years of age All Phase 1/2

Simplify language using AI